Aim: To perform a further Cox proportional hazards logistic regression analysis of data from
two large‐scale placebo‐controlled trials with cisapride as maintenance treatment in reflux …

Background: Successful treatment of gastro-oesophageal reflux disease (GORD) has
traditionally been assessed as healing of reflux oesophagitis, which may not be relevant in …

Background: The healing of oesophagitis, both symptomatic and endoscopic, can be
obtained with cisapride, the results being equivalent to what has been achieved with H2 …

Prokinetic agents are being used increasingly in medical therapy for gastro‐oesophageal
reflux disease (GERD). This study examined the effect of 10 mg qds, oral cisapride, or …

Aim: In an international, multicentre, double‐blind trial, to document the therapeutic
equivalence of two dosing regimens of cisapride on endoscopic healing and symptom …

Cisapride is a new drug which stimulates gastrointestinal motility via facilitation of
acetylcholine release from myenteric nerves. European studies have addressed its clinical …

Maintenance treatment with cisapride was evaluated in 298 patients in whom reflux
oesophagitis had been healed with antisecretory drugs. Initially, 34% of the patients had …

Objectives: To evaluate the safety and efficacy of cisapride in patients with
gastroesophageal reflux disease. Methods: Patients (N= 177) were randomized to double …

Altogether, 138 patients were included in a study aimed at evaluating the effect of cisapride
on healing and relapse of oesophagitis shown endoscopically. In the first phase of the study …

In a 6 to 12-week double-blind trial, the effect of cisapride (10 mg qid) was compared with
that of placebo in 63 patients with esophagitis confirmed by endoscopy and/or biopsy. In …